Título:	In vitro and in vivo toxicity assessment of the senotherapeutic Peptide 14
Autor(es):	Zonari, Alessandra Brace, Lear E. Silva, Thuany Alencar Porto, William Farias Foyt, Daniel Guiang, Mylieneth Ochoa Cruz, Edgar Andres Franco, Octávio Luiz Oliveira, Carolina R. Boroni, Mariana Carvalho, Juliana Lott de
Afiliação do autor:	OneSkin, Inc., San Francisco, CA 94107, USA OneSkin, Inc., San Francisco, CA 94107, USA Catholic University of Brasilia, Genomic Sciences and Biotechnology Program OneSkin, Inc., San Francisco, CA 94107, USA Porto Reports, Brasília OneSkin, Inc., San Francisco, CA 94107, USA OneSkin, Inc., San Francisco, CA 94107, USA OneSkin, Inc., San Francisco, CA 94107, USA Catholic University of Brasilia, Genomic Sciences and Biotechnology Program Catholic University of Brasilia, Genomic Sciences and Biotechnology Program, Center of Proteomic Analyses and Biochemistry Catholic University Dom Bosco, Campo Grande, S-Inova Biotech, Biotechnology Program OneSkin, Inc., San Francisco, CA 94107, USA OneSkin, Inc., San Francisco, CA 94107, USA Brazilian National Cancer Institute (INCA), Bioinformatics and Computational Biology Lab Catholic University of Brasilia, Genomic Sciences and Biotechnology Program University of Brasília, Faculty of Medicine, Interdisciplinary Biosciences Laboratory
Assunto:	Senescência celular Envelhecimento Peptídeos Toxicidade
Data de publicação:	5-Ago-2022
Editora:	Elsevier B.V.
Referência:	ZONARI, Alessandra et al. In vitro and in vivo toxicity assessment of the senotherapeutic Peptide 14. Toxicology Reports, [S. l.], v. 9, p. 1632-1638, 2022. DOI: https://doi.org/10.1016/j.toxrep.2022.07.018. Disponível em: https://www.sciencedirect.com/science/article/pii/S221475002200172X?via%3Dihub. Acesso em: 11 jul. 2024.
Abstract:	Senotherapeutic molecules decrease cellular senescence burden, constituting promising approaches to combat the accumulation of senescent cells observed in chronological aging and age-related diseases. Numerous molecules have displayed senotherapeutic potential, but toxicity has been frequently observed. Recently, a new senotherapeutic compound, Peptide 14, was developed to modulate cellular senescence in the skin. In order to assess the potential toxic and genotoxic effects of the peptide, we observed the viability of human primary dermal fibroblasts and epidermal keratinocytes with Peptide 14 treatment, and show that it is mostly non-toxic in concentrations up to 100 μM. Cancer lines were also used to investigate its potential of modulating proliferation. Different concentrations of the peptide promoted a discrete reduction in the proliferation of cancerous cells of the MeWo and HeLa lineages. In full-thickness human skin equivalents, topically formulated Peptide 14 also failed to exert any significant irritation, nor cellular toxicity when added to the culture media. Genotoxic assays including the Ames, micronucleus, and karyotyping tests also indicate the safety of the peptide. Finally, the irritative potential of the peptide was assessed in human subjects in a repeated insult patch test executed using 1 mM peptide. No visible skin reactions were observed in any of the 54 participants. Taken together, the present data support that Peptide 14 is a senotherapeutic molecule with a positive safety profile as tested with cruelty-free models, justifying further studies involving the peptide.
Unidade Acadêmica:	Faculdade de Medicina (FM)
Licença:	© 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
DOI:	https://doi.org/10.1016/j.toxrep.2022.07.018
Aparece nas coleções:	Artigos publicados em periódicos e afins

Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.